

Management of iatrogenic urethral foreign body after mid-urethral sling: A literature reviewAmélie Bazinet^{1,2}, Sylvia Weis^{3,4}, François-Xavier Madec⁵, Bernard Boillot^{2,5}¹Department of Urology, Université de Montréal, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada;²Service d'Urologie, CHU de Grenoble, La Tronche, France; ³Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ⁴Assistance Publique - Hôpitaux de Paris, Paris, France; ⁵Service d'Urologie, Hôpital Foch, Suresnes, France**Cite as:** Bazinet A, Weis S, Madec F-X, et al. Management of iatrogenic urethral foreign body after mid-urethral sling: A literature review. *Can Urol Assoc J* 2023 July 11; Epub ahead of print. <http://dx.doi.org/10.5489/cuaj.8293>

Published online July 11, 2023

Corresponding author: Dr. Amélie Bazinet, Department of Urology, Université de Montréal, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada; amelie.bazinet@umontreal.ca

ABSTRACT**Introduction:** Urethral mesh perforation is a rare complication of mid-urethral sling resulting in a lack of clear management guidelines. Thus, we aimed to determine management options and their respective outcomes in terms of erosion resolution and continence.**Methods:** A literature review was performed by extracting studies from the PubMed, Cochrane, and Google Scholar from January 1996 to December 1, 2022. Only French and English language studies were included. A total of 227 papers were screened and assessed for eligibility.**Results:** Forty-eight studies were included in the final analysis, for a total of 224 patients. Treatment options consisted of conservative, endoscopic, transurethral, and transvaginal approaches. Conservative treatment was associated with a 100% risk of persistence or recurrence of urethral perforation, while the failure rates for endoscopic, transurethral, and transvaginal approaches were 33%, 7.5%, and 7%, respectively. Most patients suffered from stress urinary incontinence after reconstructive management. The most common symptoms at the time of**KEY MESSAGES**

- Mid-urethral sling perforation into the urethra can be managed by endoscopic, transurethral, or transvaginal approach.
- Minimally invasive procedures, like transurethral or endoscopic sling resection, are safe and successful for most patients.
- Transvaginal sling complete excision with tissue interposition has the lowest risk of erosion recurrence.
- All approaches are associated with a high relapse rate of stress urinary incontinence.

presentation were overactive bladder and pain. The mean time between the onset of symptoms and diagnosis was 10 months. About half of the urethral mesh perforations were diagnosed within the first years after the initial sling insertion.

Conclusions: Multiple management options for sling penetration of the urethra have been described in the literature. Transvaginal sling resection with consecutive tissue interposition seems to carry the lowest risk of erosion recurrence; however, all treatment options are associated with a high relapse rate for stress urinary incontinence.

INTRODUCTION

Since their introduction to the market in 1996, mid-urethral synthetic slings (MUS) have seen an impressive soaring and are used worldwide for the treatment of stress urinary incontinence (SUI) in women. (1) After a gradual increase in the late 1990s up to 2010, their use declined slightly when the FDA, as well as Health Canada, issued a warning in July 2011 and February 2010 and a later update in March 2013 and May 2014, respectively. (2-5) However, they still remain the most common incontinence management procedure today. (6) Nowadays, awareness of MUS complications has increased due to several national registries worldwide as well as numerous case reports, cohort studies and reviews.

Perforation is a rare complication of tension-free transvaginal tape (TVT). Vaginal exposure and vesical or urethral perforation occurs in about 2% and less than 0.5%, respectively. (7-9) Several risk factors have been reported to increase the rate of urethral perforation, including the non-recognition of urethral perioperative trocar injury, excessive tension, MUS twist, dissection that is too close to the urethra or too extensive, and impaired blood supply such as in menopausal women or after local radiotherapy. Patient undergoing a repeat sling procedure as well as a postoperative urethral dilatation or transurethral downward tugging have also been associated with an increased rate of urethral erosion. (10, 11)

Possible management of urethral perforation includes transurethral endoscopic, direct transurethral, and transvaginal partial or complete sling excision. Because of the rarity of this complication, there is a lack of clear management guidelines in the literature and thus, the approach chosen is often based on local customs and surgeon's experience. By conducting a literature review, we aim to investigate the specific management outcomes in terms of perforation recurrence, continence, and the need for subsequent surgery. We also sought to identify the symptoms associated with urethral perforation as well as the timing between the initial MUS insertion and perforation diagnosis.

METHODS

A review of the literature published since January 1996 up to December 1, 2022, was performed using different electronic database platforms (Pubmed, Cochrane, Google Scholar). Boolean logic was applied to the keyword *urethral erosion, penetration or perforation* combining them with the following search team: *Mid urethral sling, MUS, Transvaginal tape, tension-free vaginal tape, TVT, sling, trans-obturator tape, TOT, management, surgery, reconstruction, or repair*. Furthermore, additional articles were found by hand-searching the reference lists of each article. Two independent reviewers conducted the search and rated the article title and abstract. If no consensus was attained, a third reviewer was available for consultation. Included articles were in English or French, involved adult women (≥ 18 years of age) and described the treatment approach for urethral erosion and its outcomes. All types of MUS were included, and all treatment options were considered. This included conservative, direct or endoscopic transurethral approach, and transvaginal treatment options. If different locations of urinary tract perforation (bladder, vaginal or urethral) were reported in an article, we extracted the relevant data separately. The study was rejected if the urethral perforation was concomitant with bladder perforation or recognized at the time of the mesh insertion. Studies were also discarded if the outcome of the surgical repair was not reported.

All identified abstracts were processed using a reference manager software package (EndNote X9, Thomson Reuters, Philadelphia, PA, USA).

Data collected from the relevant articles were the year of publication, the study type, the number of patients, their age, the type of MUS, erosion associated symptoms, the timing between mesh insertion and erosion diagnosis, the type of perforation (partial or transfixing), management and outcomes including success rate, continence, and need for further surgery. A partial perforation was defined as a visible sling portion within the urethral wall, while a transfixing perforation was defined as the sling crossing the lumen of the urethra. Success was defined as the absence of persistent or recurrent tape perforation at follow-up appointments.

RESULTS

Search results

The results of the literature search are shown as flow chart in Figure 1 **Error! Reference source not found.** After identifying 227 articles during the initial search and an additional 16 studies by hand-searching in the articles reference lists, we excluded 135 articles after title and abstract review and another 55 after full-text assessment. A total of 48 papers were included in the final analysis (**Error! Reference source not found.** Table 1).

Characteristics of the studies and patient population

We found 27 case reports (12-38) and 21 retrospective studies. (11, 39-58) Study characteristics were categorized according to the management options used: conservative (Table 3), transurethral (Table 4), and transvaginal (Table 5).

A total of 224 patients were included, with a median of 2 patients per study and a mean age of 54.9 years. Most patients received a retropubic MUS (RP-MUS) (60%) and the most common symptoms associated with MUS perforation were irritative symptoms (65%) and SUI recurrence (51%) while 12% of erosions were associated with urethrovaginal fistula. Mean follow-up after perforation management was 16 months. The demographic data as well as clinical presentation are shown in Table 2 **Error! Reference source not found.**

Management outcomes

Overall, the use of conservative management, including observation, suprapubic catheter placement and antibiotic treatment was reported in 2 studies for a total of 3 patients (**Error! Reference source not found.** Table 3). In all cases, partial perforation occurred in these patients within one year of MUS insertion. According to our review, conservative treatments are associated with a 100% failure rate. The authors cited the frailty of the patients and the desire to avoid surgery as reasons for choosing this approach.

Endoscopic transurethral management methods for urethral perforation were subdivided according to the medium used to cut the sling: Holmium laser (Endo-L), endoscopic scissors (Endo-S) or electrode loop (Endo-E). Complete sling transfixion as well as partial erosion were addressed by this strategy. The laser approach was used in 7 studies for a total of 43 patients and failed in 37% of the patient. Furthermore, 21% of the patients suffered from SUI recurrence afterwards. In the Endo-E group, 2 out of 4 patients (50%) also experienced perforation recurrence and required subsequent treatment. Endo-S resection seems to yield better results as only 1 out of 11 patients (9%) continued to have persistent foreign bodies in the urethra. However, 55% suffered from recurrent SUI. Endoscopic management outcomes are presented in Table 4 **Error! Reference source not found.**

A direct transurethral approach was used in 5 studies for a total of 14 urethral perforations. It consisted of grabbing the sling transurethrally with a clamp, applying traction on it, and cutting both mucosal edges of the sling with scissors inserted through the urethra. Both partial and transfixing perforations were managed in this way. Healing without subsequent mesh exposure was archived in 93% of the patients and 36% experienced SUI recurrence. Results are presented in Table 4 **Error! Reference source not found.**

Most of the studies reported transvaginal management for urethral mesh perforation. Moreover, all patients in whom the perforation presented as a urethrovaginal fistula were managed this way. We identified 2 principal reconstructive procedures. The first included a partial or complete mesh vaginal portion excision using an inverted "U" or a transversal vaginal incision followed by multi-layer closure of the urethral defect and vagina with absorbable sutures. This procedure was used in a total of 65 patients. The surgery was successful in 57 patients (88%). The latter suffered from a persistent urethrovaginal fistula and required subsequent transvaginal surgery with tissue interposition in most cases. SUI recurred in 60% of the patient.

The second subtype included the same transvaginal procedures but with the addition of a tissue interposition between the closure of the urethra and the vaginal wall. Such a method was used in 15 studies for a total of 79 patients. Most of them underwent a Martius fibro-fatty flap (n=53) followed by an autologous fascia sling interposition (n=22). Flaps of vaginal epithelium (n=2), omentum (n=1) and striated sphincter fiber (n=1) flaps were also used. When a flap was used, most surgeons advocated a complete removal of the vaginal portion of sling material (76%). Overall, 2 patients (2.5%) experienced failure in the form of a persistent urethrovaginal fistula. SUI after repairs, on the other hand, was frequent and occurred in 39 patients (60%). (Table 5)

Four studies described the management of non-synthetic PVS perforation for a total of 14 patients. One patient had an urethrovaginal fistula associated with the perforation. A transvaginal approach associated with sling division only, partial excision or complete excision was used in 7, 1 and 5 patients, respectively. None of them had undergone flap interposition. One patient was treated with a direct transurethral excision, according to the technique described previously. Regardless of the technique used, a success rate of 100% was archived, but 6 patients (43%) subsequently suffered from SUI. (Table 6)

Stress urinary incontinence

SUI status was available before and after perforation management in 141 patients. Of those suffering from SUI at the time of reference, 79% had SUI persistence while 21% were cured after urethral perforation repair. Moreover, 19% developed de novo SUI after management. Of those, 91% and 9% underwent a transvaginal and a transurethral perforation repair, respectively.

Timing

Time between initial MUS insertion and the development of symptoms was reported in 45 patients and the time between initial surgery and the perforation diagnosis in 96 patients. Half of the perforations occurred within the first year after MUS surgery. The occurrence of urethral mesh perforation after 6 years was rare (10%) (Figure 2). When urethral perforation occurred within the first year, half of the patients complained of symptoms since the MUS insertion. Mean delay between the onset of symptoms and diagnosis of perforation was 10 months.

DISCUSSION

As mentioned before, urethral perforation is a rare complication, occurring in less than 0.5 % of MUS insertions. Due to the rarity of this event, the literature on the management of such a complication is sparse. Indeed, since the introduction of MUS in 1996, we could only retrieve a total of 224 patients from studies that met our inclusion criteria. Moreover, all included articles were retrospective or case reports, making it impossible to draw strong recommendations about urethral erosion management. However, we believe that this review can still provide sensible general recommendations.

First, it seems that conservative management is neither an appropriate nor effective option, and we recommend not offering it to patients. Indeed, our study suggests a high risk of erosion persistence and a high likelihood of the need for subsequent intervention. Even in patients with high comorbidity, a minimally invasive approach such as endoscopic transection seems preferable as it provides a satisfactory cure rate and can be performed without general anesthesia. Our statement against conservative management is concordant with the Canadian Urology Association (CUA) as well as the American Urology Association (AUA) guidelines. (59, 60)

According to these same sources, sling removal can be performed by endoscopic or transvaginal resection. (59, 60) In our review, the use of transurethral scissor, either by an endoscopic or a direct approach, seems to be associated with a higher cure rate than lasers or electrode loop mesh resection. We believe that this difference may be explained by the laser or electrical heat causing additional urethral tissues injury. However, due to the small number of patients, an appropriate statistical comparison was out of reach and thus, we were not able to confirm the superiority of one method over the other. These approaches can be used for partial and transfixing urethral erosions, but, logically, were not used in the presence of a urethrovaginal fistula. Thus, we recommend that endoscopic or direct transurethral resection may be used as a first-line option, regardless of the severity of the erosion, in the absence of a fistula. In case of failure after transurethral mesh excision, observation, transurethral redo, or transvaginal approaches were reported. Unfortunately, our review was not able to identify the optimal sequence because of the poverty of data. However, a recent review analyzing endoscopic and direct transurethral management of mesh erosion in the urinary tract reported that 27% of the patients required additional treatment for persistent erosion. The latter has undergone a transurethral resection redo and only 8.4% of them required subsequent procedures for erosion. Moreover, the final success rate varies between 92 and 98%, complications were exceptional, and the transurethral redo was associated with a low 3% risk of fistula development. (61) Because of this high probability of success and the minimal surgical risk, we believe that it may be reasonable to repeat endoscopic or transurethral resection on one occasion before aiming for more invasive management like transvaginal urethrotomy if surrounding urethra seems healthy enough.

The transvaginal repair was the first technique described for the treatment of MUS urethral erosion (30, 52, 62) and, according to our review is still the most used today. In our review, patients treated this way were more likely to have a urethrovaginal fistula at initial erosion presentation and multiple previous failed repair attempts. Both partial and complete removal of the vaginal portion of the mesh were described but we were not able to compare their respective outcomes. However, we observed that all failed erosion repairs were associated with a partial mesh excision and thus, we believe that it seems preferable to aim for a complete MUS vaginal portion excision when a transvaginal approach is elected.

In our review, 79 patients underwent a flap interposition for transvaginal repairs. These flaps seem to be associated with a lower incidence of fistula occurrence after repairs (2.5%) than when no flaps were used (12%). Unfortunately, our review could not point out when the use of a flap was beneficial. However, it has been stated in previous urovaginal fistula series that flaps are strongly recommended when the quality of the tissue or blood supply is poor, when there is significant local inflammation, or when a tension-free defect closure is impossible. (63, 64)

Dealing with non-synthetic PVS erosion is an interesting subject since, with the decline of synthetic MUS that we are experimenting nowadays, their use may increase. Few articles were available on the urethral erosion management in such cases, but they suggested that both simple incision and partial excision through a transurethral or transvaginal approach were associated with a high success rate. In addition to the limited number of patients included, the maximum follow-up time was only 27 months and thus, more extensive, and long-term data are needed. One observation that emanates from this review is the high rate of persistent (79%) or de novo (19%) SUI following MUS erosion repair, regardless of the management approach. Thus, informing the patient about this complication is mandatory. Our review could not clarify whether the implantation of an autologous sling at the time of erosion repair is useful and safe in preventing such a complication. However, previous experience with urethral diverticulum repair has demonstrated that autologous PVS placement at the time of repair is safe and is associated with an SUI resolution rate of more than 90%. Those slings were placed without tension overlapping the repaired region. (65, 66)

Twenty-two patients in our review had a PVS at the time of erosion repairs with only one patient requiring a sling incision for obstructive symptoms and none experiencing incontinence. Therefore, we believe that if SUI is present, concomitant incontinence surgery with autologous tissues should be considered. That said, the optimal sling position in case of erosion has not been studied yet and strong recommendations cannot be drawn at this time. On the other hand, because of its higher risk of erosion or infection, synthetic material should not be used at that time. (67)

Further studies are necessary to confirm the safety, optimal position, and efficacy of autologous PVS at the time of urethral erosion surgery. Interestingly, we found that urethral erosion occurred in most patients within the first year after MUS insertion and that new diagnoses were rare after 6 years. This is consistent with the findings of Saidan et al. who reported an incidence peak in the first years. (68)

Moreover, patients diagnosed within the first year frequently experience symptoms since initial surgery, suggesting that these early erosions may be due to unrecognized urethral trocar injury at the time of sling insertion. This underlines the fact that when a urethral trocar injury is identified during the initial MUS placement, the procedure should be aborted due to the high risk of erosion, as recommended in both the CUA and AUA guidelines. (59, 60)

Even though this study is, to our knowledge, the widest review on the management of sling associated urethral erosion, it still has its limitations. Indeed, the quality of the studies included is weak as only retrospective and case reports were found. Moreover, the small total number of patients included in addition to the limited follow-up time prevents us from drawing

robust guidelines and conclusions on the optimal management algorithm. Nevertheless, this review provides general guidance that may help clinicians in their choice and sequence of treatment. A suggested management algorithm is shown in Figure 3 **Error! Reference source not found.**

CONCLUSIONS

Even though it is a rare event, several management options for urethral sling penetration have been described in the literature. Acceptable treatment includes endoscopic, transurethral, and transvaginal sling excision. Transvaginal sling resection with tissue interposing seems to carry the lowest risk of erosion recurrence. All types of treatment are associated with a high recurrence rate of stress urinary incontinence.

DRAFT

REFERENCES

1. Ulmsten U, Henriksson L, Johnson P et al. An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct* 1996;7:81-5
2. Chughtai B, Buck J, Anger J et al. Trends and Reinterventions in the Surgical Management of Stress Urinary Incontinence among Female Medicare Beneficiaries. *Urology Practice* 2016;3:349-54.
3. FDA.gov. USA Food and Drug Administration. Notification FPH. UPDATE on Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse. [updated 2013 March]. <https://wayback.archive-it.org/7993/20170111231226/http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm> Accessed December 3, 2022.
4. Canada.ca. Canada Health: Surgical Mesh - Complications Associated with Transvaginal Implantation of Surgical Mesh for the Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse [updated 2010 February] <https://recalls-rappels.canada.ca/en/alert-recall/surgical-mesh-complications-associated-transvaginal-implantation-surgical-mesh>. Accessed January 10, 2023.
5. Canada.ca. Canada Health: Surgical Mesh - Complications Associated with Transvaginal Implantation of Surgical Mesh for the Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse [updated 2014 May] <https://recalls-rappels.canada.ca/en/alert-recall/surgical-mesh-complications-associated-transvaginal-implantation-treatment-stress>. Accessed January 10, 2023.
6. Linder BJ, Elliott DS. Synthetic Midurethral Slings: Roles, Outcomes, and Complications. *Urol Clin North Am* 2019;46:17-30.
7. Ford AA, Rogerson L, Cody JD et al. Mid-urethral sling operations for stress urinary incontinence in women. *Cochrane Database Syst Rev* 2017;7:CD006375.
8. Mostafa A, Lim CP, Hopper L et al. Single-incision mini-slings versus standard midurethral slings in surgical management of female stress urinary incontinence: an updated systematic review and meta-analysis of effectiveness and complications. *Eur Urol* 2014;65:402-27.
9. Barisiene M, Cerniauskiene A, Matulevicius A. Complications and their treatment after midurethral tape implantation using retropubic and transobturator approaches for treatment of female stress urinary incontinence. *Wideochir Inne Tech Maloinwazyjne* 2018;13:501-6.
10. Dell JR, O'Kelley KR. TVT erosion secondary to a twist in tape. *Int Urogynecol J Pelvic Floor Dysfunct* 2005;16:168-9.
11. Velemir L, Amblard J, Jacquetin B et al. Urethral erosion after suburethral synthetic slings: risk factors, diagnosis, and functional outcome after surgical management. *Int Urogynecol J Pelvic Floor Dysfunct* 2008;19:999-1006.
12. Estevez JP, Colin P, Lucot JP et al. Fistules urétrovaginales après cure d'incontinence urinaire d'effort par bandelettes sous-urétrales. À propos de deux cas et revue de la

- littérature. *Journal de Gynécologie Obstétrique et Biologie de la Reproduction* 2010;39:151-5.
13. Raghavan R, Deole N, Arunkalaivanan AS. Surgical management of late complications of tension free vaginal tape. *J Obstet Gynaecol* 2010;30:523-4.
 14. Quiroz LH, Cundiff GW. Transurethral resection of tension-free vaginal tape under tactile traction. *Int Urogynecol J Pelvic Floor Dysfunct* 2009;20:873-5.
 15. Wijffels SA, Elzevier HW, Lycklama a Nijeholt AA. Transurethral mesh resection after urethral erosion of tension-free vaginal tape: report of three cases and review of literature. *Int Urogynecol J Pelvic Floor Dysfunct* 2009;20:261-3.
 16. Sokol ER, Urban R. Novel repair of tension-free midurethral sling erosion into the urethra. *J Minim Invasive Gynecol* 2008;15:755-7.
 17. Siegel AL. Urethral necrosis and proximal urethro-vaginal fistula resulting from tension-free vaginal tape. *Int Urogynecol J Pelvic Floor Dysfunct* 2006;17:661-4.
 18. Powers K, Lazarou G, Greston WM. Delayed urethral erosion after tension-free vaginal tape. *Int Urogynecol J Pelvic Floor Dysfunct* 2006;17:422-5.
 19. McLennan MT. Transurethral resection of transvaginal tape. *Int Urogynecol J Pelvic Floor Dysfunct* 2004;15:360-2.
 20. Tunn R, Gauruder-Burmester A, Kölle D. Ultrasound diagnosis of intra-urethral tension-free vaginal tape (TVT) position as a cause of postoperative voiding dysfunction and retropubic pain. *Ultrasound Obstet Gynecol* 2004;23:298-301.
 21. Wai CY, Atnip SD, Williams KN et al. Urethral erosion of tension-free vaginal tape presenting as recurrent stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct* 2004;15:353-5.
 22. Gerstenbluth RE, Goldman HB. Simultaneous urethral erosion of tension-free vaginal tape and woven polyester pubovaginal sling. *J Urol* 2003;170:525-6.
 23. Hilton P, Mohammed KA, Ward K. Postural perineal pain associated with perforation of the lower urinary tract due to insertion of a tension-free vaginal tape. *Bjog* 2003;110:79-82.
 24. Vassallo BJ, Kleeman SD, Segal J et al. Urethral erosion of a tension-free vaginal tape. *Obstet Gynecol* 2003;101:1055-8.
 25. Webster TM, Gerridzen RG. Urethral erosion following autologous rectus fascial pubovaginal sling. *Can J Urol* 2003;10:2068-9.
 26. Werner M, Najjari L, Schuessler B. Transurethral resection of tension-free vaginal tape penetrating the urethra. *Obstet Gynecol* 2003;102:1034-6.
 27. Haferkamp A, Steiner G, Müller SC et al. Urethral erosion of tension-free vaginal tape. *Journal of urology* 2002;167:250.
 28. Madjar S, Tchetgen MB, Van Antwerp A, et al. Urethral erosion of tension-free vaginal tape. *Urology* 2002;59:601.
 29. Golomb J, Groutz A, Mor Y et al. Management of urethral erosion caused by a pubovaginal fascial sling. *Urology* 2001;57:159-60.
 30. Koelbl H, Stoerer S, Seliger G et al. Transurethral penetration of a tension-free vaginal tape. *Bjog* 2001;108:763-5.
 31. Minaglia S, Oyama IA. Urethral mesh erosion after single-incision mid-urethral sling. *Female Pelvic Med Reconstr Surg* 2012;18:310-2.


32. Ibrahim JL, Taneja S, Fayyad A. Combined laparoscopic and vaginal technique for management of Tension-free Vaginal Tape (TVT) urethral mesh erosion and urethral reconstruction using Martius labial flap interposition. *ICS Abstract* 2018;291
33. Plowright LN, Duggal B, Aguilar VC et al. Endoscopic transurethral resection of urethral mesh erosion with the use of a pediatric nasal speculum. *Obstet Gynecol* 2013;121:440-3.
34. Dillon BE, Gurbuz C, Zimmern PE. Long term results after complication of "prophylactic" suburethral tape placement. *Can J Urol* 2012;19:6424-30.
35. Wadie BS. Endoscopic excision of an eroding calcified mesh sling, 10 years after primary surgery. *Int Urogynecol J Pelvic Floor Dysfunct* 2009;20:255-7.
36. Mendonça TM, Martinho D, Dos Reis JP. Late urethral erosion of transobturator suburethral mesh (Obtape): a minimally invasive management under local anaesthesia. *Int Urogynecol J* 2011;22:37-9.
37. Cholhan HJ, Stevenson KR. Sling transection of urethra: a rare complication. *Int Urogynecol J Pelvic Floor Dysfunct* 1996;7:331-4.
38. Pizarro-Berdichevsky J, Goldman MP, Goldman HB. Removal of obstructing synthetic sling from a urethra. *Int Urogynecol J*. 2016;27:1929-31.
39. Glavind K, Sander P. Erosion, defective healing and extrusion after tension-free urethropexy for the treatment of stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct* 2004;15:179-82.
40. Toia B, Unterberg S, Sihra N, et al. Functional outcomes of vaginal surgery for urethral extrusion of mid-urethral tape in women. *Int Urogynecol J* 2022;33:2251-6.
41. Kowalik CG, Cohn JA, Kakos A, et al. Road to recovery after transvaginal surgery for urethral mesh perforation: evaluation of outcomes and subsequent procedures. *Int Urogynecol J*. 2018;29:887-92.
42. Colhoun A, Rapp DE. Long-Term Outcomes After Repair of Transurethral Perforation of Midurethral Sling. *Female Pelvic Med Reconstr Surg* 2016;22:272-5.
43. Sergouniotis F, Jarlshammar B, Larsson PG. Urethral complications after tension-free vaginal tape procedures: A surgical management case series. *World J Nephrol* 2015;4:396-405.
44. Blaivas JG, Mekel G. Management of urinary fistulas due to midurethral sling surgery. *J Urol*. 2014;192:1137-42.
45. Forzini T, Viart L, Alezra E, et al. Erosive complications of mid urethral slings (MUS): 10 years of surgical experience. *Prog Urol* 2015;25:240-8.
46. Reisenauer C, Janowitz J, Wallwiener D, et al. Urethrovaginal fistulae associated with tension-free vaginal tape procedures: a clinical challenge. *Int Urogynecol J* 2014;25:319-22.
47. Shah K, Nikolavsky D, Gilsdorf D, et al. Surgical management of lower urinary mesh perforation after mid-urethral polypropylene mesh sling: mesh excision, urinary tract reconstruction and concomitant pubovaginal sling with autologous rectus fascia. *Int Urogynecol J* 2013;24:2111-7.
48. Jo DJ, Lee YS, Oh TH, et al. Outcomes of transurethral removal of intravesical or intraurethral mesh following midurethral sling surgery. *Korean J Urol* 2011;52:829-34.
49. Doumouchtsis SK, Lee FY, Bramwell D, et al. Evaluation of holmium laser for managing mesh/suture complications of continence surgery. *BJU Int* 2011;108:1472-8.

50. Baracat F, Mitre AI, Kanashiro H, et al. Endoscopic treatment of vesical and urethral perforations after tension-free vaginal tape (TVT) procedure for female stress urinary incontinence. *Clinics (Sao Paulo)*. 2005;60:397-400.
51. Amundsen CL, Flynn BJ, Webster GD. Urethral erosion after synthetic and nonsynthetic pubovaginal slings: differences in management and continence outcome. *J Urol* 2003;170:134-7.
52. Sweat SD, Itano NB, Clemens JQ, et al. Polypropylene mesh tape for stress urinary incontinence: complications of urethral erosion and outlet obstruction. *J Urol* 2002;168:144-6.
53. Clemens JQ, DeLancey JO, Faerber GJ, et al. Urinary tract erosions after synthetic pubovaginal slings: diagnosis and management strategy. *Urology* 2000;56:589-94.
54. Goujon E, Jarniat A, Bardet F, et al. Retrospective study on the management and follow-up of 18 patients with a mid-urethral sling penetrating the urethra or bladder. *J Gynecol Obstet Hum Reprod* 2018;47:289-97.
55. Ogle CA, Linder BJ, Elliott DS. Holmium laser excision for urinary mesh erosion: a minimally invasive treatment with favorable long-term results. *Int Urogynecol J* 2015;26:1645-8.
56. Allagany F, Dekalo S, Welk B. Endoscopic management of intraurethral mesh extrusion with the holmium:YAG laser is an acceptable treatment option in selected patients. *Neurourol Urodyn* 2022;41:1511-6.
57. Hermieu N, Schoentgen N, Aoun R, et al. Surgical management of suburethral sling complications and functional outcomes. *Prog Urol* 2020;30:402-10.
58. Hammad FT, Kennedy-Smith A, Robinson RG. Erosions and urinary retention following polypropylene synthetic sling: Australasian survey. *Eur Urol*. 2005; 47(5):641-6
59. Daneshgari F, Kong W, Swartz M. Complications of mid urethral slings: important outcomes for future clinical trials. *J Urol* 2008;180:1890-7.
60. Nitti VW. Complications of midurethral slings and their management. *Can Urol Assoc J* 2012;6:S120-2.
61. Karim SS, Pietropaolo A, Skolarikos A, et al. Role of endoscopic management in synthetic sling/mesh erosion following previous incontinence surgery: a systematic review from European Association of Urologists Young Academic Urologists (YAU) and Uro-technology (ESUT) groups. *Int Urogynecol J* 2020;31:45-53.
62. Haferkamp A, Steiner G, Müller SC, et al. Urethral erosion of tension-free vaginal tape. *J Urol* 2002;167:250.
63. Malde S, Sihra N, Naaseri, et al. Urethral diverticulectomy with Martius labial fat pad interposition improves symptom resolution and reduces recurrence. *BJU Int* 2017;119:158-63.
64. D Lee PZ. Long-term functional outcomes following non-radiated urethrovaginal fistula repair. *World J Urol* 2016;34:291-6.
65. Enemchukwu E, Lai C, Reynolds WS, et al. Autologous Pubovaginal Sling for the Treatment of Concomitant Female Urethral Diverticula and Stress Urinary Incontinence. *Urology* 2015;85:1300-3.
66. Romanzi LJ, Groutz A, Blaivas JG. Urethral diverticulum in women: diverse presentations resulting in diagnostic delay and mismanagement. *J Urol* 2000;164:428-33.

67. Dmochowski RR, Blaivas JM, Gormley EA, et al. Update of AUA guideline on the surgical management of female stress urinary incontinence. *J Urol* 2010;183:1906-14.
68. Saidan D TV, Granitsiotis P, Guerrero K. Lower Urinary Tract Mesh Perforations following the insertion of Mid-urethral Tapes or Transvaginal Mesh: A Tertiary Unit's Experience. *Int Arch Urol Complic* 2019;5:059.

DRAFT

FIGURES AND TABLES

Figure 1. Flow chart of study selection.

References	Year of publication	Level of evidence	# of patients
Case reports (n=27)			
Ibrahim et al	2018	VI	1
Pizarro-Berdichesky et al	2016	VI	1
Plowright et al	2013	VI	2
Dillon et al	2012	VI	1
Minaglia et al	2012	VI	1
Estevez et al	2010	VI	2
Mendonça et al	2010	VI	2

Raghavan et al	2010	VI	1
Quiroz et al	2009	VI	1
Wadie et al	2009	VI	1
Wijffels et al	2009	VI	3
Sokol et al	2008	VI	1
Siegel et al	2006	VI	1
Powers et al	2005	VI	2
McLennan et al.	2004	VI	1
Tunn et al	2004	VI	1
Wai et al	2004	VI	1
Gerstenbluth et al	2003	VI	1
Hilton et al	2003	VI	1
Vassallo et al	2003	VI	1
Webster et al	2003	VI	1
Werner et al	2003	VI	1
Haferkamp et al	2002	VI	1
Madjar et al	2002	VI	1
Golomb	2001	VI	1
Koelbl et al	2001	VI	1
Cholhan et al	1996	VI	1
Retrospective studies (n=21)			
Allagany et al	2022	VI	29
Hermieu et al	2022	VI	15
Toia et al	2022	VI	34
Goujon et al	2018	VI	3
Kowalik et al	2018	VI	19
Colhoun et al	2016	VI	5
Ogle et al	2015	VI	4
Sergouniotis et al	2015	VI	8
Blaivas et al	2014	VI	4
Forzini et al	2014	VI	3
Reisenauer et al	2013	VI	7
Shah et al	2013	VI	14
Doumouchtsis et al	2011	VI	4
Jo et al	2011	VI	3
Velemir et al	2008	VI	7
Baracat et al.	2005	VI	5

Hammad et al	2005	VI	9
Glavind	2004	VI	1
Amundsen et al	2003	VI	9
Sweat et al	2002	VI	2
Clemens et al	2000	VI	6

Table 1. Demographic data and presentation of the urethral erosion	
Total number of patients included	n=224
Median number of patients in study (range)	n=2 (1-34)
Mean age (y)	54.9 (38-77)
Type of MUS	n=184
RP	60%
TO	28%
SIS	4%
Non-synthetic	8%
Presenting symptoms	n=181
Irritative	65%
SUI recurrence	51%
Pain	46%
Obstructive	42%
rUTI	26%
Fistula	12%
Hematuria	4%
Mean time between initial MUS surgery and erosion	
Symptoms (m), n=45	17.8 (0–133)
Diagnostic (m) n=96	31.9 (1–180)
Mean followup after erosion management (m)	16 (1-144)

M: month; rUTI: recurrent urinary tract infection; y: year.

	# (n=3)	Mean age (44.8)	MUS type	Symptoms	Perforation type	Mean erosion timing (4.8 m)	Persistence of erosion 3/3 (100%)	Subsequent treatment
Golomb (2001)	1/1	46	Non-syn. sling	Pain	Partial	7	1	Transvaginal excision
Sergouniotis (2015)	2/8	43.5	SIS (1), TVT (1)	None (1), Pain/OAB (1)	Partial	2.5	2	Transurethral excision (1), Observation (1)

	#	Mean age	Type of erosion	Mean erosion timing (m)	Mean followup (m)	Outcomes		Subsequent treatment
						Persistence of SUI	Persistence of erosion	
Endo-L	43	63		33.6	16.3	9/42 (21%)	16/43 (37%)	
Allagany (2022)	29/29	58	Transfixing (9)	72	3	6	8	Observation (5), re-endo-laser (3)
Kowalik (2018)	1/19	73	–	–	–	–	1	Transvaginal excision
Ogli (2015)	4/4	63	–	46	29	1	2	TVT (1), re-endo-laser (1)
Forzini (2014)	3/3	65.7	Transfixing	10	33	1	2	Transvaginal excision (1), re-endo-laser (1), lost in followup (1)
Dillon (2012)	1/1	58	Transfixing	36	1.5	0	0	None

Jo (2011)	1/3	57	–	–	–	1	1	Observation
Doumouchsis (2010)	4/4	68.3	–	4	15	0	2	RTU-laser (1)
Endo-E	4	56				1/2 (50%)	2/4 (50%)	
Kowalik (2018)	2/19	61	–	–	–	–	2	Transvaginal excision (2)
Jo (2011)	1/3	67	–	–	–	0	0	None
Wadie (2009)	1/1	40	Transfixing	120	2	1	0	Non-synthetic sling
Endo-S	11	66		19	8	6/11 (55%)	1/11 (9%)	
Velemir (2008)	4/7	53.5	–	53.5	11.3	3	1	TOT (1), para-urethral bulking agent (1), re-TUR (1)
Baracat (2005)	5/5	–	–	8	6	3	0	non-synthetic sling (3)
McLennan (2004)	1/1	77	Partial	1	10	0	0	None
Werner (2003)	1/1	68	Transfixing	14	6	0	0	None
TU-S	14	52		40.5	8.4	5/14 (36%)	1/14 (7%)	
Sergouniotis (2015)	6/8	45.3	Partial (4), Transfixing (1)	60.7	5.2	3	1	TVT (3), observation (1)
Plowright (2013)	2/2	55	Transfixing	48	30	0	0	None
Mendonça (2010)	2/2	57	Transfixing	12	3	1	0	None
Quiroz (2009)	1/1	50	Transfixing	72	1.5	0	0	None
Wijffels (2009)	3/3	52	Transfixing	10	2.5	1	0	TVT (1)

Table 5A. Urethrotomy with mesh excision alone, n= 65								
	#	Mean age (51.5)	Mean erosion timing (21.2 m)	Mesh excision extends	Mean followup (15.9 m)	Outcomes		Subsequent treatment
						Persistence of SUI 39/65 (60%)	Persistence of erosion 8/65 (12%)	
Hermieu (2022)	15/15	57	43	Partial	12	12	0	TVT (5), AUS (1), Burch (1), bulking agents (1)
Goujon (2018)	2/3	58.5	78	-	92.5	2	1	Redo + vaginal flap (1)
Kowalik (2018)	10/19	55	–	Partial	25	4	0	Non-syn. sling (1), redo + flap (1)
Colhoun (2016)	5/5	49	4.2	Complete	54	4	0	Non-syn. sling (3)
Pizarro-B (2016)	1/1	66	12	Partial	8	0	0	None
Sergouniotis (2015)	2/8	51	4	Partial	3	2	0	Colposuspension (1), bulking agents (1)
Reisenauer (2013)	7/7	54	40	Partial	11	6	Fistula (5)	Redo (1) + redo+ flap (4)
Jo (2011)	1/3	60	–	Partial	–	0	0	None
Estevez (2010)	2/2	42	29.5	Complete	13	2	0	TVT (1)
Raghavan (2010)	1/1	54	72	Partial	–	0	0	None
Velemir (2008)	1/7	48	3	Complete	3	0	0	None
Hammad (2005)	5/9	–	–	Partial	–	0	0	None

Powers (2005)	2/2	42	3.5	Complete	1.5	2	0	None
Glavind (2004)	1/1	56	3	Partial	12	1	Fistula (1)	Abdominal repair (1)
Tunn (2004)	1/1	43	8	Partial	1.5	0	0	None
Wai (2004)	1/1	54	5	Partial	-	1	0	None
Amundsen (2003)	1/9	–	18	Partial	39	1	0	Bulking agents
Vassallo (2003)	1/1	36	3	Partial	1	1	0	Non-syn. sling
Haferkamp (2002)	1/1	56	1	Partial	1	0	0	None
Madjar (2002)	1/1	55	3	Complete	3	0	0	None
Sweat (2002)	1/2	–	–	Partial	–	1	Fistula (1)	Redo + flap (1)
Koelbl (2001)	1/1	45	12	Partial	0.5	0	0	None
Cholhan (1996)	1/1	50	24	Partial	5	0	0	None

Table 5B. Urethrotomy with mesh excision and flap, n=79

	#	Mean age (55.5)	Mean erosion timing (30,8 m)	Mesh excision extends	Flap	Mean followup (11 m)	Outcomes		Subsequent treatment
							Persistence of SUI 45/75 (60%)	Persistence of erosion 2/79 (2.5%)	
Toia (2022)	34/34	53	72	Complete	Martius	6	28	Fistula (1)	Non-syn. sling (13), CI (1), AUS (2), bulking agents (1), colposuspension (4)

Goujon (2018)	1/3	72	11	Complete	Martius	9	1	0	None
Ibrahim (2018)	1/1	54	144	Complete	Martius	3	0	0	None
Kowalik (2018)	10/19	56	–	Partial	Martius (2), autologous sling (7), vaginal (1)	25	7	0	Non-syn. sling (1)
Blaivas (2014)	4/4	–	15	-	Martius (3), Omentum (1)	-	-	Fistula (1)	Autologous sling (4)
Reisenauer (2013)	4/7	49.5	18	Partial	Martius (4)	9.5	3	0	TVT (2)
Shah (2013)	14/14	53	18	Complete	Autologous sling (14)	16	1	0	Non-syn. sling (1), sling lysis (1), urethroplasty (1)
Minaglia (2012)	1/1	42	26	Complete	Martius	2.5	1	0	None
Sokol (2008)	1/1	50	12	Complete	Sphincter fiber	8	0	0	None
Velemir (2008)	2/7	55	5	Complete	Martius (2)	12	1	0	Bulking injection (1)
Siegel (2006)	1/1	64	0	Complete	Martius	3	1	0	Non-syn. sling (1)
Amundsen (2003)	2/9	-	7	Partial	Martius (2)	34	1	0	Non-syn. sling (1)
Gerstenbluth (2003)	1/1	70	60	Complete	Martius	3	0	0	None
Hilton (2003)	1/1	48	12	Complete	Martius	–	1	0	None
Sweat (2002)	2/2	–	–	Complete	Martius (1), autologous sling (1)	12	0	0	None

	# (n=14)	Mean age (59.5)	Erosion type	Fistula	Mean erosion timing (7 m)	Mesh excision extends	Flap interposition	Mean followup (15.7 m)	Outcomes		Subsequent treatment
									Persistence of SUI 6/14 (43%)	Persistence of erosion 0/14 (0%)	
Golomb (2001)	1/1	46	Partial	no	7	TV. division	no	12	0	0	None
Webster (2003)	1/1	73	Transfixing	no	0.5	TU. Partial	–	–	0	0	–
Clemens (2000)	6/6	–	–	yes	13	TV. partial (1), TV. complete (5)	no	8	5	0	Non-syn. sling (2)
Amundsen (2003)	6/9	–	–	no	8	TV. division	no	27	1	0	None

M: month; non-syn: non-synthetic; TU: transurethral; TV: transvaginal.